PPLPHARMA - Swing Trade Analysis with AI Signals
Last Updated Time : 20 Dec 25, 07:01 am
Back to Swing Trade ListSwing Trade Rating: 3.3
| Stock Code | PPLPHARMA | Market Cap | 22,743 Cr. | Current Price | 171 ₹ | High / Low | 273 ₹ |
| Stock P/E | 32.2 | Book Value | 58.2 ₹ | Dividend Yield | 0.08 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 186 ₹ | DMA 200 | 198 ₹ |
| Chg in FII Hold | -0.59 % | Chg in DII Hold | 0.64 % | PAT Qtr | 196 Cr. | PAT Prev Qtr | 113 Cr. |
| RSI | 22.7 | MACD | -6.50 | Volume | 28,15,670 | Avg Vol 1Wk | 30,04,571 |
| Low price | 165 ₹ | High price | 273 ₹ | PEG Ratio | 1.45 | Debt to equity | 0.12 |
| 52w Index | 5.59 % | Qtr Profit Var | -6.54 % | EPS | 5.32 ₹ | Industry PE | 30.6 |
📊 PPLPHARMA shows moderate fundamentals with reasonable valuation but weak short-term technicals. The RSI at 22.7 indicates oversold conditions, while MACD is negative, suggesting bearish momentum. The stock is trading below DMA 50 and DMA 200, making it a cautious swing trade candidate with potential rebound near support levels.
💡 Optimal Entry Price: Around 165–172 ₹ (near 52-week low and oversold RSI).
🚪 Exit Strategy: If already holding, consider exiting near 185–195 ₹ (DMA 50 resistance zone) or trail stop-loss below 160 ₹.
✅ Positive
- 📈 P/E of 32.2 is close to industry PE (30.6), showing fair valuation.
- 💼 Market cap of 22,743 Cr. provides stability.
- 📊 PAT improved to 196 Cr. vs 113 Cr. previously, showing operational recovery.
- 🛡️ Low debt-to-equity ratio (0.12) ensures financial resilience.
⚠️ Limitation
- 📉 Current price below DMA 50 and DMA 200, reflecting weak technical trend.
- 🔻 Dividend yield of 0.08% is negligible.
- 📊 EPS of 5.32 ₹ is modest compared to peers.
- 📉 PEG ratio of 1.45 suggests limited growth-adjusted value.
🚨 Company Negative News
- 📉 Quarterly profit variation (-6.54%) highlights earnings volatility.
- ⚠️ FII holdings decreased (-0.59%), showing reduced foreign investor confidence.
🌟 Company Positive News
- 💼 PAT recovery to 196 Cr. supports earnings momentum.
- 📈 DII holdings increased (+0.64%), showing domestic institutional support.
- 📊 Strong trading volumes indicate active participation despite weak technicals.
🏭 Industry
- 📊 Industry PE at 30.6 vs PPLPHARMA’s 32.2, showing fair alignment.
- 🌐 Pharma sector remains resilient with steady demand and defensive characteristics.
📝 Conclusion
⚖️ PPLPHARMA is a cautious swing trade candidate with fair valuation and improving profits but weak technicals. Entry near 165–172 ₹ offers rebound potential, with exits planned around 185–195 ₹. Risk management is essential due to earnings volatility and declining foreign investor interest, though low debt and sector resilience provide medium-term support.
I can also compare PPLPHARMA’s swing trade setup with another pharma stock to highlight relative opportunities for short-term trading.
Back to Swing Trade ListNIFTY 50 - Today Top Swing Trade Stock Picks
NEXT 50 - Today Top Swing Trade Stock Picks
MIDCAP - Today Top Swing Trade Stock Picks
SMALLCAP - Today Top Swing Trade Stock Picks